TrialJournal of child and adolescent psychopharmacology2022

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.

Ann C Childress et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.